Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
Patients who have been treated for hepatitis C virus (HCV) infection who have failed to
respond to anti-viral treatment are often concerned about their ongoing liver disease and are
therefore looking for alternative treatments which might prevent fibrosis progression. This
view is endorsed by patient representative groups (including Charles Gore at the HepC Trust)
who have welcomed this trial protocol.
The study is a single centred, prospective, open labelled design. Practical as well as safety
concerns dictated that the study could not be conducted in a blinded fashion, since patients
taking anticoagulation require monitoring. The study consisted of two 8 week phases: Phase 1
and Phase 2. Phase 1 (observation phase, 0 to 8 weeks) and Phase 2 (treatment phase with
warfarin anticoagulation, 8 to 16 weeks). Study completed at end of Phase 2.